PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ventor: Ellis L. Kline

Serial No. 09/827,302) Art Unit: 1654

Filed: APRIL 5, 2001) Examiner: MELLER, M.

For: METHODS AND COMPOSITIONS)
FOR TREATING NEOPLASMS)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

As this Supplemental Information Disclosure Statement is being filed after the issuance of an office action on the merits, pursuant to 37 C.F.R. §1.97(c)(2), the fee of \$180, as set forth in §1.17(p), is authorized herein by Form PTO-2038.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

06/10/2005 MHDLDGE1 00000014 09827302

01 FC:1806

180.00 GP

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, on June 6, 2005.

Sima Singaana Kulkarni – Reg. No. 43,732

ATLLIB02 185068.1

Supplemental Information Disclosure Statement Serial No. 09/827,302 Page 2 of 2

No additional fees are believed due; however, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, to Deposit Account No. 11-0855.

Respectfully submitted,

Sima Singadia Kulkarni

Reg. No. 43,732

KILPATRICK STOCKTON LLP 1100 Peachtree Street Suite 2800 Atlanta, Georgia 30309-4530 404-815-6500

Attorney Docket: 13395-0101 (44448-256971)

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Decisions are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Complete if Known Substitute for Form 1449/A/PTO **Application Number** 09/827,302 Filing Date April 5, 2001

I INIL/AL	38/18 1/ 1 894 16/1 / 16/1		1
	RMATIONOUSCLOSO		Ellis L. Kline
STAT	ement b y arb eicai	Group Art Unit	1651
:	(use as many sheets as necessary	Examiner Name	M. Meller
Sheet 1	of 1	Attorney Docket Number	13395-0101 (44448-256971)

U.S. PATENT DOCUMENTS								
Examiner	Cite	U.S. Patent	Kind Code ²	Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant		
Initials	No. ¹	Number	(if known)	of Cited Document	MM-DD-YYYY	Figures Appear		

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	1	Simmons, R., et al., "Regression of Established Methylcholanthrene Tumors by Intratumor Injections of Vibrio Cholerae Neuraminidase," <i>Journal of Surgical Oncology</i> ,	
		Vol. 4, No. 4, pp. 298-305 (1972)	
	2	Simmons, R., <i>et al.</i> , "Immunospecific Regression of Methylcholanthrene Fibrosarcoma With The Use of Neuraminidase. II. Intratumor Injections of Neuraminidase," <i>Surgery</i> , Vol. 71, No. 4, pp. 556-564 (1972)	

۱ ـ .	i e
Date	
0:	
Considered	
	Date Considered

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.